Search clinical trials for: Oligonucleotides, Antisense

Total 121 results

Mary Crowley Medical Research Center

Terminated

Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer (Auto TAG)

Carcinoma, Advanced Metastatic

United States
Imperial College London
Sarepta Therapeutics, Inc.; Department of Health, United Kingdom

Completed

Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United Kingdom
National Cancer Institute (NCI)

Terminated

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
Isarna Therapeutics GmbH

Completed

Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2

Melanoma | Colorectal Neoplasms | Pancreatic Neoplasms

Germany
ProQR Therapeutics
European Commission

Completed

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

Cystic Fibrosis

United States, Spain, United Kingdom, Germany, Italy, Belgium, Canada, Czechia, Denmark, France
National Cancer Institute (NCI)

Completed

A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases

Neoplasms | Liver Metastases

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Pilot Immunotherapy Trial for Recurrent Malignant Gliomas

Malignant Glioma of Brain

United States
Sterna Biologicals GmbH & Co. KG

Completed

Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients (SECURE)

Colitis, Ulcerative

Germany
Isarna Therapeutics GmbH

Completed

Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy

Primary Open Angle Glaucoma

Germany
National Institute of Allergy and Infectious Diseases...

Completed

Testing the AVI-7100 Flu Drug in Healthy Volunteers

Influenza

United States
National Cancer Institute (NCI)

Terminated

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

Gastrointestinal Neoplasms | Ovarian Neoplasms | Ovarian Cancer | Ascites | Gastrointestinal Cancer

United States
AstraZeneca
Ionis Pharmaceuticals, Inc.

Completed

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma

Advanced Adult Hepatocellular Carcinoma | Hepatocellular Carcinoma Metastatic

Korea, Republic of, Taiwan, Hong Kong, Japan
University of Pittsburgh
National Cancer Institute (NCI)

Terminated

Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head And Neck | Carcinoma, Squamous Cell of Head and Neck

United States
Sterna Biologicals GmbH & Co. KG

Completed

Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema

Mild to Moderate Atopic Dermatitis

Germany
Brigham and Women's Hospital
GlaxoSmithKline; Ionis Pharmaceuticals, Inc.

Withdrawn

The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart

Amyloidosis
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

Healthy

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers

Healthy Volunteer

Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

Healthy

United States
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Gene Therapy in Treating Patients With Advanced Head and Neck Cancer

Head and Neck Cancer

United States
Achieve Life Sciences

Completed

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

Neoplasms

United States, Canada
National Cancer Institute (NCI)

Completed

Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia

United States
Sterna Biologicals GmbH & Co. KG

Completed

Safety, Efficacy, PK, and PD Characteristics of Orally Inhaled SB010 in Male Patients With Mild Asthma (Multiple Dose)

Asthma

Germany
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Isarna Therapeutics GmbH

Terminated

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma (SAPPHIRE)

Glioblastoma | Anaplastic Astrocytoma

Spain, Taiwan, Korea, Republic of, United States, Hungary, Germany, Argentina, Brazil, India, Canada, Austria, France, Mexico, Poland, Russian Federation, United Kingdom
Eleos, Inc.

Withdrawn

Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course

Acute Myelogenous Leukemia
Eleos, Inc.

Completed

Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML

Acute Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
University of Southern California
Sponsor Name Pending

Withdrawn

A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma

Mesothelioma

United States
Sterna Biologicals GmbH & Co. KG

Completed

Safety, Tolerability, and Pharmacokinetics After a Single Dose of Orally Inhaled DNAzyme Solution for Nebulisation in Male Patients With Asthma

Asthma

Germany
Santaris Pharma A/S

Unknown

Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C

Hepatitis C

Puerto Rico
Isarna Therapeutics GmbH

Completed

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Glioblastoma | Anaplastic Astrocytoma

Germany, Austria, Georgia, India, Israel, Russian Federation
National Cancer Institute (NCI)

Completed

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Terminated

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

Gastrointestinal Stromal Tumor

United States
National Cancer Institute (NCI)

Completed

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Waldenström Macroglobulinemia

United States
National Cancer Institute (NCI)

Completed

Oblimersen in Treating Patients With Merkel Cell Carcinoma

Recurrent Neuroendocrine Carcinoma of the Skin | Stage III Neuroendocrine Carcinoma of the Skin | Stage IV Neuroendocrine Carcinoma of the Skin | Stage II Neuroendocrine Carcinoma of the Skin | Stage I Neuroendocrine Carcinoma of the Skin

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Cardiac Toxicity

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Stage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular Lymphoma

United States
Sterna Biologicals GmbH & Co. KG

Completed

Safety, Tolerability, and Pharmacokinetics After Multiple Doses of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects

Asthma

Germany
Sterna Biologicals GmbH & Co. KG

Completed

Safety, Tolerability, and Pharmacokinetics of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects

Asthma

Germany
Santaris Pharma A/S

Completed

Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects

Hepatitis C | Chronic Hepatitis C

United States
Genta Incorporated

Completed

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Solid Tumors

United States
Vancouver Coastal Health
NCIC Clinical Trials Group; Vancouver General Hospital Foundation

Unknown

A Study for Treatment of Superficial Bladder Cancer Using OGX-427

Bladder Cancer

Canada

Search clinical trials for: Oligonucleotides, Antisense

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations